Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction

NCT00215124 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT00215124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00215124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction
Lead sponsor
The Cleveland Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
Not reported
Completion date
February 28, 2007
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction